Eagle Pharmaceuticals (EGRX): Notes From Management Meetings - RBC

RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on Eagle Pharmaceuticals (NASDAQ: EGRX) after hosting two days of meetings with management.

Three key points include: 1) the pipeline is led by Ryanodex in EHS and ecstasy/meth

2) there is further "upside" from the bendamustine franchise

3) capital deployment remains a wildcard

The analyst believes EGRX has established a solid underlying cash flow base with upside to come from the pipeline, greater BENDEKA duration, and capital deployment. EPS for 2016-18E increases to $3.51, $4.31 and $5.39 and the price target goes to $80 from $78.

For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.

Shares of Eagle Pharmaceuticals closed at $64.95 yesterday.

You May Also Be Interested In

• Barrington Research Starts CBIZ, Inc. (CBZ) at Outperform
• Clearway Energy Inc. (CWEN) PT Raised to $45 at UBS After Model Update
• Goldman Sachs Downgrades Inspur Electronic Information Industry Co Ltd (000977:CH) to Sell